Drug class
PCSK9 inhibitor; recombinant fusion protein lipid-lowering biologic
Mechanism of action
Binds proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity and prevents PCSK9 binding to hepatic LDL receptors, reducing receptor degradation and increasing LDL-receptor availability to clear LDL cholesterol from the blood.
General use cases
- Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, under the US FDA LEROCHOL indication (approved 12 December 2025)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
